NASDAQ:IMVT

12.78
0.22 (1.69%) 1d
0
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Feb 16/21, Down 18.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with IMVT has triggered our recommended stop at $15. To be disciplined, we recommend covering the position. We will look for better opportunities.
Pharma & Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly IMVT is an emerging biotech company that develops treatment for autoimmune diseases, such as thyroid eye disease. Their products can be disruptive as they offer far less invasive treatments to products on the market today. The company is awaiting approval of its products, so it is not generating revenue currently making this a more speculative recommendation. We would buy this with a stop-loss at $15. This TOP PICK has substantial upside potential, so we will set an initial upside target of $35 (over 55% upside) to assess its further opportunity. Yield 0%. (Analysts’ price target is $44.75)
Pharma & Healthcare
Showing 1 to 2 of 2 entries
  • «
  • 1
  • »

Immunovant, Inc.(IMVT-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Immunovant, Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Immunovant, Inc.(IMVT-Q) Frequently Asked Questions

What is Immunovant, Inc. stock symbol?

Immunovant, Inc. is a American stock, trading under the symbol IMVT-Q on the NASDAQ (IMVT). It is usually referred to as NASDAQ:IMVT or IMVT-Q

Is Immunovant, Inc. a buy or a sell?

In the last year, there was no coverage of Immunovant, Inc. published on Stockchase.

Is Immunovant, Inc. a good investment or a top pick?

Immunovant, Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Immunovant, Inc..

Why is Immunovant, Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Immunovant, Inc. worth watching?

0 stock analysts on Stockchase covered Immunovant, Inc. In the last year. It is a trending stock that is worth watching.

What is Immunovant, Inc. stock price?

On 2022-11-22, Immunovant, Inc. (IMVT-Q) stock closed at a price of $12.78.